Liquidia Corp (LQDA)
12.70
-0.04
(-0.31%)
USD |
NASDAQ |
May 17, 16:00
12.70
0.00 (0.00%)
After-Hours: 20:00
Liquidia Cash from Financing (TTM): 132.97M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 132.97M |
December 31, 2023 | 43.25M |
September 30, 2023 | 19.66M |
June 30, 2023 | 9.946M |
March 31, 2023 | 64.83M |
December 31, 2022 | 64.96M |
September 30, 2022 | 65.93M |
June 30, 2022 | 67.57M |
March 31, 2022 | 35.64M |
December 31, 2021 | 26.32M |
September 30, 2021 | 24.19M |
June 30, 2021 | 90.79M |
March 31, 2021 | 65.22M |
Date | Value |
---|---|
December 31, 2020 | 63.42M |
September 30, 2020 | 95.21M |
June 30, 2020 | 26.39M |
March 31, 2020 | 33.72M |
December 31, 2019 | 66.39M |
September 30, 2019 | 36.16M |
June 30, 2019 | 81.09M |
March 31, 2019 | 76.01M |
December 31, 2018 | 68.82M |
September 30, 2018 | 72.25M |
June 30, 2018 | 36.86M |
March 31, 2018 | 37.54M |
December 31, 2017 | 28.81M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
9.946M
Minimum
Jun 2023
132.97M
Maximum
Mar 2024
55.68M
Average
64.12M
Median
Cash from Financing (TTM) Benchmarks
United Therapeutics Corp | -1.128B |
AIM ImmunoTech Inc | 0.485M |
Perspective Therapeutics Inc | 167.19M |
Protalix BioTherapeutics Inc | 10.43M |
Armata Pharmaceuticals Inc | 59.32M |